Rev­enue shrink­ing, Sanofi sweeps a PhII can­cer ADC and TB vac­cine pro­gram out of the pipeline in Q2 cleanup

A lit­tle more than a year ago Sanofi $SNY hand­ed Im­muno­Gen a $30 mil­lion pay­ment to gain ex­clu­sive de­vel­op­ment rights to a slate of ex­per­i­men­tal can­cer drugs in the pipeline, in­clud­ing the Phase II drug SAR566658, an ADC tar­get­ing CA6 spot­light­ed in the deal that was in de­vel­op­ment for triple neg­a­tive breast can­cer.

To­day, it’s his­to­ry.

The French phar­ma gi­ant wrote the drug off, say­ing that it was end­ing de­vel­op­ment ef­forts for the that drug as well as a TB vac­cine pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER